Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Imaging approaches for delivery of personalised cancer treatment CRUK Cancer Imaging Centre Institute of Cancer Research London and Royal Marsden Hospital, London, UK. M O Leach, N deSouza, D-M Koh, G Flux, S Robinson, G ter Haar, J Bamber Theme 5 – Developing whole body multiparametric imaging Theme 5 - Informatics and imaging developments PRECISION MEDICINE 2. Image heterogeneity of phenotype to predict and monitor treatment response 3. Image response to targetted treatment DWI b900 Whole body imaging can evaluate: heterogeneous disease body burden Subtracted CE ADC 4.Imaging biomarker driven therapy Whole-cohort processing pipelines 3-D interaction with registered multimodality data Microscopy • whole-slide • confocal • time-lapse Optical CT Carbozantinib (XL184) promising MET, AXL and VEGFR2 inhibitor 62 yr metastatic CRPC • absorption • emission • FLIM/FRET Pretreatment OCT IVIS Photoacoustic Differential imaging response Elastography 5.METHODOLOGY AND INFORMATICS Repository for multi-centre trials DICOM modalities New approaches for functional contrast imaging Normalised Contrast enhanced Imaging 1. Link imaging phenotype to genotype MRIS CT PET SPECT US Seamless integration with both ICR and open-source applications Spectral CZT Combined imaging shows response and action despite differential imaging effects Import images with complete metadata regardless of origin b = 900 s2 / mm 18F-FDG PET/CT Same interface for both patient and pre-clinical data Increased emphasis on ontology, controlled vocabulary and contentbased image search micro x-ray CT MALDI genomic Post 6 weeks XL184 treatment non-DICOM modalities With J deBono and DDU DELIVERING A VISION OF PRECISION MEDICINE Clinical need: Response & predictive biomarkers in sclerotic disease orthotopic model of VCaP prostate cancer Molecular Pathology Therapeutic development Genetics & Epidemiology vehicle Pre treatment PSA 357 12 wks of abiraterone PSA 31.5 cabozantinib Tc-99m MDP Tc-99m MDP CANCER IMAGING INNOVATE AND TRANSLATE DELIVER IMAGING BIOMARKERS INTO THE CLINIC at * * * *** CT *** ADC 879 Day 0 Identify response and resistance ADC1496 Day 15 DW-MRI DW-MRI C Messiou Aid detection Stratify patients for targetted therapy CT Day 0 T Graham, S Robinson Day 15 Impact: Relate pattern of change in imaging biomarkers to subsequent relapse Drive and guide therapy delivery The research programme encompasses a range of cancer and scientific questions. Questions range from improved detection and diagnosis, prognosis, planning, guidance and response A range of modalities include MR, PET, SPECT, US, opticaland opto-acoustic techniques. research is closely integrated and highly translational. There is emphasis on new biomarkers. Research is closely integrated with a range of other programmes, including drug development, radiotherapy, basic cancer biology, clinical units in major cancers.